Veru (NASDAQ:VERU) Releases Quarterly Earnings Results

Veru (NASDAQ:VERU) announced its earnings results on Thursday, revealing an earnings per share (EPS) of ($0.07) for the quarter. This result exceeded analysts' expectations, which were predicting an EPS of ($0.08), marking a small improvement of $0.01 over the forecast.

Performance of Veru Stock

During mid-day trading on Thursday, Veru's stock saw a slight decrease of $0.04, bringing its price down to $0.51. The trading volume reached 4,007,623 shares, indicating robust activity compared to its average volume of 5,243,357 shares. Over the past year, the stock has experienced a low of $0.37 and a high of $1.92. Currently, Veru holds a market capitalization of $74.07 million, a price-to-earnings (P/E) ratio of -1.80, and a beta of -0.54. Its 50-day moving average stands at $0.72, while the 200-day moving average is at $0.77.

Analysts Predict Future Growth

Several research analysts recently provided insights on Veru. HC Wainwright maintained a "buy" rating on Veru shares and issued a price target of $3.00. Meanwhile, Oppenheimer also reiterated an "outperform" rating and set a price objective of $5.00 for the stock.

About Veru Inc.

Veru Inc. is a biopharmaceutical company in the late stages of clinical development, focusing on creating treatments for metabolic diseases, cancer, and acute respiratory distress syndrome (ARDS). Among its products is the FC2 female condom, which offers protection against both unplanned pregnancies and sexually transmitted infections.

Earnings, Stocks, Analysis